In the PIONEER AF-PCI study [41], the combination of either low-dose rivaroxaban plus a P2Y12 antagonist or very-low-dose rivaroxaban plus DAPT significantly decreased the bleeding risk compared to standard therapy with a vitamin K antagonist plus DAPT for 1, 6, or 12 months. This evidence concerns the gene P2RY12 and atrial fibrillation.